Meo Sultan Ayoub, ElToukhy Riham A, Meo Anusha Sultan, Klonoff David C
Department of Physiology, College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia.
Department of Family Medicine, College of Medicine, King Saud University, Riyadh 2925, Saudi Arabia.
Vaccines (Basel). 2023 Apr 11;11(4):826. doi: 10.3390/vaccines11040826.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging viral zoonotic illness that has developed a distinctive and threatening situation globally. Worldwide, many vaccines were introduced to fight against the COVID-19 pandemic. The present study aims to compare the bio-pharmacological characteristics, indications, contraindications, efficacy, and adverse effects of inactivated whole-virus COVID-19 vaccines, Sinopharm, CoronaVac, and Covaxin. Initially, 262 documents and 6 international organizations were selected. Finally, 41 articles, fact sheets, and international organizations were included. The data were recorded from the World Health Organization (WHO), Food and Drug Administration (FDA) USA, Web of Science, PubMed, EMBASE, and Scopus. The results demonstrated that these three inactivated whole-virus COVID-19 vaccines, Sinopharm, CoronaVac, and Covaxin, received emergency approval from the FDA/WHO, and all three of these vaccines are beneficial for the prevention of the COVID-19 pandemic. The Sinopharm vaccine has been recommended during pregnancy and for people of all age groups, and the CoronaVac and Covaxin vaccines are recommended for people over 18 years of age and older. These three vaccines have recommended intramuscular doses of 0.5 mL each, with a 3-4 week interval. These three vaccines can be stored in a refrigerator at +2 to +8 °C. The common adverse effects of these vaccines are pain at the injection site, redness, fatigue, headache, myalgias, general lethargy, body ache, arthralgia, nausea, chills, fever, and dizziness. The overall mean efficiency for the prevention of the COVID-19 disease is 73.78% for Sinopharm, 70.96% for CoronaVac, and 61.80% for Covaxin. In conclusion, all three inactivated whole-virus COVID-19 vaccines, Sinopharm, CoronaVac, and Covaxin, are beneficial for the prevention of the COVID-19 pandemic. However, evidence suggests that the overall impact of Sinopharm is slightly better than that of CoronaVac and Covaxin.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）是一种新出现的病毒性人畜共患病，已在全球范围内造成了独特且具有威胁性的局面。在全球范围内，许多疫苗被用于对抗新冠疫情。本研究旨在比较国药集团、科兴疫苗和印度巴拉特生物技术公司的新冠灭活全病毒疫苗的生物药理学特征、适应症、禁忌症、疗效和不良反应。最初，筛选了262份文献和6个国际组织。最后，纳入了41篇文章、情况说明书和国际组织。数据来自世界卫生组织（WHO）、美国食品药品监督管理局（FDA）、科学网、PubMed、EMBASE和Scopus。结果表明，这三种新冠灭活全病毒疫苗，即国药集团疫苗、科兴疫苗和印度巴拉特生物技术公司的新冠疫苗，均获得了FDA/WHO的紧急批准，并且这三种疫苗对预防新冠疫情均有益处。国药集团疫苗被推荐用于孕期以及所有年龄段的人群，而科兴疫苗和印度巴拉特生物技术公司的新冠疫苗则被推荐用于18岁及以上的人群。这三种疫苗推荐的肌肉注射剂量均为0.5毫升，间隔3至4周。这三种疫苗可在2至8摄氏度的冰箱中储存。这些疫苗的常见不良反应包括注射部位疼痛、发红、疲劳、头痛、肌痛、全身乏力、身体疼痛、关节痛、恶心、寒战、发热和头晕。国药集团疫苗预防新冠疾病的总体平均有效率为73.78%，科兴疫苗为70.96%，印度巴拉特生物技术公司的新冠疫苗为61.80%。总之，这三种新冠灭活全病毒疫苗，即国药集团疫苗、科兴疫苗和印度巴拉特生物技术公司的新冠疫苗，对预防新冠疫情均有益处。然而，有证据表明，国药集团疫苗的总体效果略优于科兴疫苗和印度巴拉特生物技术公司的新冠疫苗。
